Please assess the completion status of the following clinical trial:

Trial Title: Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, ages 18 years or older who have signed the informed consent~* Has qualifying bacterial pneumonia~* Female patients must not be pregnant at the time of enrollment~* Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug~Exclusion Criteria:~* Known or suspected hospital-acquired pneumonia~* Evidence of significant immunological disease~* Has a history of hypersensitivity or allergic reaction to any tetracycline or to any fluoroquinolone antibiotic~* Has received an investigational drug within past 30 days~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omadacycline (Type: EXPERIMENTAL): Omadacycline IV; Omadacycline tablets
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin IV; Moxifloxacin tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).